T. Keya, A. Leela, K. Fernandez, N. Habib, M. Rashid
2021.12.30Current Reviews in Clinical and Experimental Pharmacology
tlooto Summary
Benefits of normal vitamin C supplementation for reducing the duration of respiratory tract illness were supported by the meta-analysis findings.
Abstract
BACKGROUND Respiratory tract infections are a primary cause of illness and mortality over the world.
OBJECTIVE This study was aimed to investigate the effectiveness of vitamin C supplementation in preventing and treating respiratory tract infections.
METHODS We used the Cochrane, PubMed, and MEDLINE Ovid databases to conduct our search. The inclusion criteria were placebo-controlled trials. Random effects meta-analyses were performed to measure the pooled effects of vitamin C supplementation on the incidence, severity, and duration of respiratory illness.
RESULTS We found ten studies that met our inclusion criteria out of a total of 2758. The pooled risk ratio (RR) of developing respiratory illness when taking vitamin C regularly across the study period was 0⸳94 (with a 95% confidence interval of 0⸳87 to 1⸳01) which found that supplementing with vitamin C lowers the occurrence of illness. This effect, however, was statistically insignificant (P= 0⸳09). This study showed that vitamin C supplementation had no consistent effect on the severity of respiratory illness (SMD 0⸳14, 95% CI -0⸳02 to 0⸳30: I2 = 22%, P=0⸳09). However, our study revealed that vitamin C group had a considerably shorter duration of respiratory infection (SMD -0⸳36, 95% CI -0⸳62 to -0⸳09, P = 0⸳01).
CONCLUSION Benefits of normal vitamin C supplementation for reducing the duration of respiratory tract illness were supported by our meta-analysis findings. Since few trials have examined the effects of therapeutic supplementation, further research is needed in this area.
Citation format
KEYA, T., et al. Effect of vitamin c supplements on respiratory tract infections: A systematic review and meta-analysis. Current Reviews in Clinical and Experimental Pharmacology, 2021.